Liu, Wang-Da
Feng, Po-Hao
Cheng, Chien-Yu
Chou, Chun-Liang
Lee, Chih-Hsin
Lu, Min-Chi
Liu, Po-Yu
Lee, Mei-Hui
Liao, Chun-Hsing
Chen, Mei-Chuan
Chen, Cheng-Pin
Hsu, Shang-Fu
Tzeng, Yu-Tien
Lin, Yi-Chun
Ou, Tsong-Yih
Qin, Albert
Tsai, Chan-Yen
Shih, Weichung Joe
Lee, Kang-Yun
Sheng, Wang-Huei
Funding for this research was provided by:
PharmaEssentia Corporation
Article History
Received: 20 March 2024
Accepted: 8 May 2024
First Online: 21 May 2024
Declarations
:
: Albert Qin and Chan-Yen Tsai work for PharmaEssentia Corporation. Wang-Huei Sheng serves as a consultant of PharmaEssentia Corporation. The other authors do not have conflict of interest to declare.
: The study was conducted in accordance with the Helsinki Declaration of 2008. The study protocol and informed consent form (ICF) were approved by the Institutional Review Boards of National Taiwan University Hospital, Taipei Medical University, and all other participating hospitals. The committee names and the approval numbers are provided in supplemental TableĀ . ICF including the consents of study participation and publication was obtained from all patients prior to their participation. This study was registered at ClinicalTrials.gov (NCT05770466).